|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:ACTN4-RYR1 (FusionGDB2 ID:HG81TG6261) |
Fusion Gene Summary for ACTN4-RYR1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ACTN4-RYR1 | Fusion gene ID: hg81tg6261 | Hgene | Tgene | Gene symbol | ACTN4 | RYR1 | Gene ID | 81 | 6261 |
Gene name | actinin alpha 4 | ryanodine receptor 1 | |
Synonyms | ACTININ-4|FSGS|FSGS1 | CCO|MHS|MHS1|PPP1R137|RYDR|RYR|RYR-1|SKRR | |
Cytomap | ('ACTN4')('RYR1') 19q13.2 | 19q13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | alpha-actinin-4focal segmental glomerulosclerosis 1non-muscle alpha-actinin 4 | ryanodine receptor 1central core disease of muscleprotein phosphatase 1, regulatory subunit 137ryanodine receptor 1 (skeletal)sarcoplasmic reticulum calcium release channelskeletal muscle calcium release channelskeletal muscle ryanodine receptortyp | |
Modification date | 20200327 | 20200328 | |
UniProtAcc | O43707 | . | |
Ensembl transtripts involved in fusion gene | ENST00000252699, ENST00000390009, ENST00000424234, ENST00000497637, | ||
Fusion gene scores | * DoF score | 42 X 60 X 18=45360 | 11 X 9 X 5=495 |
# samples | 77 | 11 | |
** MAII score | log2(77/45360*10)=-5.88041838424733 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(11/495*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ACTN4 [Title/Abstract] AND RYR1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ACTN4(39138547)-RYR1(39051753), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | ACTN4-RYR1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACTN4-RYR1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACTN4-RYR1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACTN4-RYR1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ACTN4 | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 25411248 |
Hgene | ACTN4 | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 22351778 |
Hgene | ACTN4 | GO:0048384 | retinoic acid receptor signaling pathway | 22351778 |
Hgene | ACTN4 | GO:0051272 | positive regulation of cellular component movement | 9508771 |
Tgene | RYR1 | GO:0001666 | response to hypoxia | 19120137 |
Fusion gene breakpoints across ACTN4 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across RYR1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | LIHC | TCGA-ED-A7PX-01A | ACTN4 | chr19 | 39138547 | - | RYR1 | chr19 | 39051753 | + |
ChimerDB4 | LIHC | TCGA-ED-A7PX-01A | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
Top |
Fusion Gene ORF analysis for ACTN4-RYR1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000252699 | ENST00000355481 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000252699 | ENST00000359596 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000252699 | ENST00000360985 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000390009 | ENST00000355481 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000390009 | ENST00000359596 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000390009 | ENST00000360985 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000424234 | ENST00000355481 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000424234 | ENST00000359596 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
In-frame | ENST00000424234 | ENST00000360985 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
intron-3CDS | ENST00000497637 | ENST00000355481 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
intron-3CDS | ENST00000497637 | ENST00000359596 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
intron-3CDS | ENST00000497637 | ENST00000360985 | ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051753 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ACTN4-RYR1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051752 | + | 6.66E-19 | 1 |
ACTN4 | chr19 | 39138547 | + | RYR1 | chr19 | 39051752 | + | 6.66E-19 | 1 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ACTN4-RYR1 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:39138547/chr19:39051753) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ACTN4 | . |
FUNCTION: F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. This is a bundling protein (Probable). Probably involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation (PubMed:15772161). Involved in tight junction assembly in epithelial cells probably through interaction with MICALL2. Links MICALL2 to the actin cytoskeleton and recruits it to the tight junctions (By similarity). May also function as a transcriptional coactivator, stimulating transcription mediated by the nuclear hormone receptors PPARG and RARA (PubMed:22351778). {ECO:0000250|UniProtKB:P57780, ECO:0000269|PubMed:15772161, ECO:0000269|PubMed:22351778, ECO:0000305|PubMed:9508771}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 19_26 | 54 | 912.0 | Compositional bias | Poly-Gly |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 19_26 | 54 | 693.0 | Compositional bias | Poly-Gly |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4462_4532 | 4089 | 5034.0 | Compositional bias | Note=Pro-rich | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4462_4532 | 4094 | 5039.0 | Compositional bias | Note=Pro-rich | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4462_4532 | 4089 | 5034.0 | Compositional bias | Note=Pro-rich | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4881_4900 | 4089 | 5034.0 | Intramembrane | Pore-forming | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4881_4900 | 4094 | 5039.0 | Intramembrane | Pore-forming | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4881_4900 | 4089 | 5034.0 | Intramembrane | Pore-forming | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4895_4901 | 4089 | 5034.0 | Motif | Selectivity filter | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4895_4901 | 4094 | 5039.0 | Motif | Selectivity filter | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4895_4901 | 4089 | 5034.0 | Motif | Selectivity filter | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4210_4214 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4955_4960 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4980_4986 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4210_4214 | 4094 | 5039.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4955_4960 | 4094 | 5039.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4980_4986 | 4094 | 5039.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4210_4214 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4955_4960 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4980_4986 | 4089 | 5034.0 | Nucleotide binding | ATP | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4581_4641 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4663_4780 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4804_4804 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4822_4836 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4858_4880 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4901_4920 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4942_5038 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4581_4641 | 4094 | 5039.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4663_4780 | 4094 | 5039.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4804_4804 | 4094 | 5039.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4822_4836 | 4094 | 5039.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4858_4880 | 4094 | 5039.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4901_4920 | 4094 | 5039.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4942_5038 | 4094 | 5039.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4581_4641 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4663_4780 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4804_4804 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4822_4836 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4858_4880 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4901_4920 | 4089 | 5034.0 | Topological domain | Lumenal | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4942_5038 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4560_4580 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4642_4662 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4781_4803 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4805_4821 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4837_4857 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4921_4941 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D6 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4560_4580 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4642_4662 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4781_4803 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4805_4821 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4837_4857 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4921_4941 | 4094 | 5039.0 | Transmembrane | Helical%3B Name%3D6 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4560_4580 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4642_4662 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4781_4803 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4805_4821 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4837_4857 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4921_4941 | 4089 | 5034.0 | Transmembrane | Helical%3B Name%3D6 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 778_789 | 54 | 912.0 | Calcium binding | 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 819_830 | 54 | 912.0 | Calcium binding | 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 778_789 | 54 | 693.0 | Calcium binding | 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 819_830 | 54 | 693.0 | Calcium binding | 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 163_269 | 54 | 912.0 | Domain | Calponin-homology (CH) 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 50_154 | 54 | 912.0 | Domain | Calponin-homology (CH) 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 765_800 | 54 | 912.0 | Domain | EF-hand 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 806_841 | 54 | 912.0 | Domain | EF-hand 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 163_269 | 54 | 693.0 | Domain | Calponin-homology (CH) 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 50_154 | 54 | 693.0 | Domain | Calponin-homology (CH) 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 765_800 | 54 | 693.0 | Domain | EF-hand 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 806_841 | 54 | 693.0 | Domain | EF-hand 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 84_88 | 54 | 912.0 | Motif | LXXLL motif |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 84_88 | 54 | 693.0 | Motif | LXXLL motif |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 177_192 | 54 | 912.0 | Region | Polyphosphoinositide (PIP2)-binding |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 1_269 | 54 | 912.0 | Region | Note=Actin-binding |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 177_192 | 54 | 693.0 | Region | Polyphosphoinositide (PIP2)-binding |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 1_269 | 54 | 693.0 | Region | Note=Actin-binding |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 293_403 | 54 | 912.0 | Repeat | Spectrin 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 413_518 | 54 | 912.0 | Repeat | Spectrin 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 528_639 | 54 | 912.0 | Repeat | Spectrin 3 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 649_752 | 54 | 912.0 | Repeat | Spectrin 4 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 293_403 | 54 | 693.0 | Repeat | Spectrin 1 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 413_518 | 54 | 693.0 | Repeat | Spectrin 2 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 528_639 | 54 | 693.0 | Repeat | Spectrin 3 |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 649_752 | 54 | 693.0 | Repeat | Spectrin 4 |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1873_1924 | 4089 | 5034.0 | Compositional bias | Note=Glu-rich (acidic) | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1873_1924 | 4094 | 5039.0 | Compositional bias | Note=Glu-rich (acidic) | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1873_1924 | 4089 | 5034.0 | Compositional bias | Note=Glu-rich (acidic) | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1013_1208 | 4089 | 5034.0 | Domain | B30.2/SPRY 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1356_1570 | 4089 | 5034.0 | Domain | B30.2/SPRY 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 159_204 | 4089 | 5034.0 | Domain | MIR 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 210_264 | 4089 | 5034.0 | Domain | MIR 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 270_327 | 4089 | 5034.0 | Domain | MIR 4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 335_392 | 4089 | 5034.0 | Domain | MIR 5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 4074_4102 | 4089 | 5034.0 | Domain | EF-hand | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 581_797 | 4089 | 5034.0 | Domain | B30.2/SPRY 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 97_152 | 4089 | 5034.0 | Domain | MIR 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1013_1208 | 4094 | 5039.0 | Domain | B30.2/SPRY 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1356_1570 | 4094 | 5039.0 | Domain | B30.2/SPRY 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 159_204 | 4094 | 5039.0 | Domain | MIR 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 210_264 | 4094 | 5039.0 | Domain | MIR 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 270_327 | 4094 | 5039.0 | Domain | MIR 4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 335_392 | 4094 | 5039.0 | Domain | MIR 5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 4074_4102 | 4094 | 5039.0 | Domain | EF-hand | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 581_797 | 4094 | 5039.0 | Domain | B30.2/SPRY 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 97_152 | 4094 | 5039.0 | Domain | MIR 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1013_1208 | 4089 | 5034.0 | Domain | B30.2/SPRY 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1356_1570 | 4089 | 5034.0 | Domain | B30.2/SPRY 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 159_204 | 4089 | 5034.0 | Domain | MIR 2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 210_264 | 4089 | 5034.0 | Domain | MIR 3 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 270_327 | 4089 | 5034.0 | Domain | MIR 4 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 335_392 | 4089 | 5034.0 | Domain | MIR 5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 4074_4102 | 4089 | 5034.0 | Domain | EF-hand | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 581_797 | 4089 | 5034.0 | Domain | B30.2/SPRY 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 97_152 | 4089 | 5034.0 | Domain | MIR 1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 841_2959 | 4089 | 5034.0 | Region | Note=6 X approximate repeats | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 841_2959 | 4094 | 5039.0 | Region | Note=6 X approximate repeats | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 841_2959 | 4089 | 5034.0 | Region | Note=6 X approximate repeats | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1344_1359 | 4089 | 5034.0 | Repeat | Note=3%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1372_1387 | 4089 | 5034.0 | Repeat | Note=4%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 2726_2845 | 4089 | 5034.0 | Repeat | Note=5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 2846_2959 | 4089 | 5034.0 | Repeat | Note=6 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 841_954 | 4089 | 5034.0 | Repeat | Note=1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 955_1068 | 4089 | 5034.0 | Repeat | Note=2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1344_1359 | 4094 | 5039.0 | Repeat | Note=3%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1372_1387 | 4094 | 5039.0 | Repeat | Note=4%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 2726_2845 | 4094 | 5039.0 | Repeat | Note=5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 2846_2959 | 4094 | 5039.0 | Repeat | Note=6 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 841_954 | 4094 | 5039.0 | Repeat | Note=1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 955_1068 | 4094 | 5039.0 | Repeat | Note=2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1344_1359 | 4089 | 5034.0 | Repeat | Note=3%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1372_1387 | 4089 | 5034.0 | Repeat | Note=4%3B truncated | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 2726_2845 | 4089 | 5034.0 | Repeat | Note=5 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 2846_2959 | 4089 | 5034.0 | Repeat | Note=6 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 841_954 | 4089 | 5034.0 | Repeat | Note=1 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 955_1068 | 4089 | 5034.0 | Repeat | Note=2 | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 1_4559 | 4089 | 5034.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 1_4559 | 4094 | 5039.0 | Topological domain | Cytoplasmic | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 1_4559 | 4089 | 5034.0 | Topological domain | Cytoplasmic |
Top |
Fusion Gene Sequence for ACTN4-RYR1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for ACTN4-RYR1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 12_26 | 54.0 | 912.0 | VCL |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 12_26 | 54.0 | 693.0 | VCL |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 108_126 | 54.0 | 912.0 | VCL |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000252699 | + | 1 | 21 | 40_61 | 54.0 | 912.0 | VCL |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 108_126 | 54.0 | 693.0 | VCL |
Hgene | ACTN4 | chr19:39138547 | chr19:39051753 | ENST00000390009 | + | 1 | 14 | 40_61 | 54.0 | 693.0 | VCL |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 3614_3643 | 4089.0 | 5034.0 | CALM | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 3614_3643 | 4094.0 | 5039.0 | CALM | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 3614_3643 | 4089.0 | 5034.0 | CALM | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000355481 | 87 | 105 | 669_680 | 4089.0 | 5034.0 | FKBP1A | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000359596 | 88 | 106 | 669_680 | 4094.0 | 5039.0 | FKBP1A | |
Tgene | RYR1 | chr19:39138547 | chr19:39051753 | ENST00000360985 | 87 | 105 | 669_680 | 4089.0 | 5034.0 | FKBP1A |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ACTN4-RYR1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ACTN4-RYR1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ACTN4 | C4551527 | Focal segmental glomerulosclerosis 1 | 9 | GENOMICS_ENGLAND;UNIPROT |
Hgene | ACTN4 | C0007097 | Carcinoma | 1 | CTD_human |
Hgene | ACTN4 | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
Hgene | ACTN4 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
Hgene | ACTN4 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
Hgene | ACTN4 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
Hgene | ACTN4 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
Hgene | ACTN4 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
Hgene | ACTN4 | C0205699 | Carcinomatosis | 1 | CTD_human |
Hgene | ACTN4 | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
Hgene | ACTN4 | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
Hgene | ACTN4 | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
Hgene | ACTN4 | C1868672 | NEPHROTIC SYNDROME, STEROID-RESISTANT, AUTOSOMAL RECESSIVE | 1 | ORPHANET |
Hgene | ACTN4 | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
Hgene | ACTN4 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Hgene | ACTN4 | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
Tgene | C2930980 | Malignant hyperthermia susceptibility type 1 | 46 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0751951 | Central Core Myopathy (disorder) | 32 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0024591 | Malignant hyperpyrexia due to anesthesia | 10 | CTD_human;GENOMICS_ENGLAND | |
Tgene | C1850674 | MINICORE MYOPATHY WITH EXTERNAL OPHTHALMOPLEGIA (disorder) | 5 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C1840365 | King Denborough syndrome | 2 | ORPHANET | |
Tgene | C3645536 | Autosomal Recessive Centronuclear Myopathy | 2 | CTD_human;ORPHANET | |
Tgene | C0007134 | Renal Cell Carcinoma | 1 | CTD_human | |
Tgene | C0008928 | Cleidocranial Dysplasia | 1 | GENOMICS_ENGLAND | |
Tgene | C0175709 | Centronuclear myopathy | 1 | CTD_human | |
Tgene | C0265261 | Multiple pterygium syndrome | 1 | GENOMICS_ENGLAND | |
Tgene | C0270960 | Congenital myopathy (disorder) | 1 | GENOMICS_ENGLAND | |
Tgene | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human | |
Tgene | C0410203 | X-linked centronuclear myopathy | 1 | CTD_human | |
Tgene | C0410204 | Myopathy, Centronuclear, Autosomal Recessive | 1 | ORPHANET | |
Tgene | C0410207 | Tubular Aggregate Myopathy | 1 | CTD_human | |
Tgene | C0546264 | Congenital Fiber Type Disproportion | 1 | CTD_human | |
Tgene | C0752282 | Congenital Structural Myopathy | 1 | CTD_human | |
Tgene | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human | |
Tgene | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human | |
Tgene | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human | |
Tgene | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human | |
Tgene | C1834558 | Myopathy, Centronuclear, Autosomal Dominant | 1 | CTD_human;ORPHANET | |
Tgene | C1854678 | MULTIPLE PTERYGIUM SYNDROME, LETHAL TYPE | 1 | ORPHANET | |
Tgene | C1861753 | Multiminicore Disease, Moderate, with Hand Involvement | 1 | ORPHANET | |
Tgene | C3661489 | Autosomal Dominant Myotubular Myopathy | 1 | CTD_human | |
Tgene | C4551952 | Myopathy, Centronuclear, 1 | 1 | CTD_human | |
Tgene | C4706390 | Congenital myopathy with myasthenic-like onset | 1 | ORPHANET | |
Tgene | C4749502 | Benign Samaritan congenital myopathy | 1 | ORPHANET |